Literature DB >> 8509554

Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets.

N A Prager1, S R Torr-Brown, B E Sobel, D R Abendschein.   

Abstract

OBJECTIVES: This study was designed to determine whether maintenance of patency in coronary arteries with high grade stenosis after thrombolysis with tissue-type plasminogen activator requires inhibition of thrombin or platelets, or both.
BACKGROUND: Activation of both thrombin and platelets has been implicated in delaying coronary recanalization induced with fibrinolytic drugs and in predisposing to reocclusion.
METHODS: Hirudin (1.5 mg/kg body weight) or aspirin (5 mg/kg), or both, was given conjunctively with tissue-type plasminogen activator in 28 conscious dogs with coronary thrombosis induced by electrical stimulation of the vessel wall in the presence of a previously placed high grade distal stenosis (85 +/- 12% [SEM] area reduction).
RESULTS: Among 22 dogs exhibiting coronary recanalization, hirudin plus aspirin, but neither agent alone, modestly shortened the interval to recanalization (31 +/- 4 min with saline solution, n = 6; 29 +/- 4 min with aspirin, n = 5; 23 +/- 9 min with hirudin, n = 6; 21 +/- 7 min with hirudin+aspirin, n = 5). Reocclusion occurred promptly and persisted in five of six dogs given only saline solution plus tissue-type plasminogen activator, in four of six dogs given hirudin and five of five dogs given aspirin; however, reocclusion was prevented in all five of the dogs given both hirudin and aspirin with tissue-type plasminogen activator (p < 0.05 compared with saline-treated dogs). In dogs given both hirudin and aspirin, the partial thromboplastin time was 2.4 +/- 0.3 times baseline, and the template bleeding time was prolonged only modestly (1.6 +/- 0.3 times baseline).
CONCLUSIONS: Thus, the combination of hirudin and aspirin in doses that do not markedly perturb hemostasis prevents early reocclusion after thrombolysis despite the presence of severe stenosis. Accordingly, conjunctive administration of both anti-thrombin and antiplatelet agents appears to be necessary for optimal maintenance of patency after thrombolysis induced in the presence of high grade coronary stenosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8509554     DOI: 10.1016/0735-1097(93)90847-t

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

1.  Guidelines for the Management of Patients with Acute Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998       Impact factor: 2.300

2.  Direct Comparison of Aspirin Plus Hirudin, Aspirin Plus Heparin, and Aspirin Alone Among 12,000 Patients with Acute Myocardial Infarction Not Receiving Thrombolysis: Rationale and Design of the First American Study of Infarct Survival (ASIS-1).

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

3.  Improving the Efficacy and Stability of Coronary Reperfusion Following Thrombolysis: Exploring the Thrombin Hypothesis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

4.  Platelet Activity in the Early Stage of Acute Myocardial Infarction: Relation to Time of Presentation, Treatment with Either Tissue Plasminogen Activator or Streptokinase and Cyclooxygenase Inhibition.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998       Impact factor: 2.300

5.  Novel Antithrombotic Strategies for the Treatment of Coronary Artery Thrombosis: A Critical Appraisal.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 6.  Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.

Authors:  A J Wagstaff; J C Gillis; K L Goa
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 7.  Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.

Authors:  J C Gillis; A J Wagstaff; K L Goa
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

8.  2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics.

Authors:  Claire R Sharp; Marie-Claude Blais; Corrin J Boyd; Benjamin M Brainard; Daniel L Chan; Armelle de Laforcade; Robert Goggs; Julien Guillaumin; Alex Lynch; Erin Mays; Duana McBride; Tommaso Rosati; Elizabeth A Rozanski
Journal:  J Vet Emerg Crit Care (San Antonio)       Date:  2022-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.